fluorouracil + panitumumab

Fluorouracil + panitumumab is a combination regimen used primarily in the treatment of metastatic colorectal cancer, particularly in patients with RAS and BRAF wild-type tumors. Fluorouracil is a cytotoxic antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and cell division. Panitumumab is a recombinant human IgG2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR), blocking ligand-induced activation and downstream signaling pathways involved in tumor cell proliferation and survival. The combination leverages both direct cytotoxic effects from fluorouracil and targeted inhibition of EGFR-mediated growth signals by panitumumab, resulting in improved response rates for eligible patients[2][5][6][8].